JYSELECA for moderate rheumatoid arthritis (RA)

JYSELECA was the first advanced* treatment and JAK inhibitor recommended by NICE in patients with moderate and severe RA1

'A New Space' by Film JYSELECA

Discover Strength of Balance in Moderate RA

Nice Guidance

Efficacy in Moderate RA Patients

Safety in Moderate RA Patients 

* Advanced therapies cover both biologic synthetic DMARDs and targeted synthetic DMARDs.

JYSELECA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).2 JYSELECA may be used as monotherapy or in combination with methotrexate (MTX).2

References: 1. NICE TA676. Filgotinib for treating moderate to severe rheumatoid arthritis. Published February 2021. Available at: https://www.nice.org.uk/guidance/ta676. Last accessed: November 2022. 2. JYSELECA SPC. Available at: www.medicines.org.uk / www.medicines.ie. Last accessed: November 2022. 3. Data on file - Gilead Sciences Ltd - GS-US-417-0301.

UK-RA-JY-202203-00020  | Date of preparation December 2022